Microlink Solutions seeks shareholder approval to renew related-party transaction mandate
Bitget2026/10/30 11:25- Microlink Solutions seeks shareholder approval to renew its mandate for recurrent related-party transactions at its December 1, 2026 annual general meeting.
- The proposal covers revenue or trading transactions needed for day-to-day operations on normal commercial terms, without disadvantaging minority shareholders.
- The renewed mandate would run until the next annual meeting, unless it expires earlier or shareholders revoke or vary it.
- The board recommends voting in favor; interested major shareholders will abstain.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Forge Nano completes acquisition of HzO
Crypto prices
More
